Supplementary File

Contents

Table S1. Search strategy and literature search results.	2
Figure S1. The heterogeneity was best resolved by excluding Hidaka et al. Sensitivity analysis of the Change in AST	
Figure S2. The heterogeneity was best resolved by excluding Suzuki et al.Sensitivity Tacrolimus trough (C0)	
Figure S3. The heterogeneity was best resolved by excluding Suzuki et al	

Table S1. Search strategy and literature search results.

Database	Restrictions	Access date	Search strategy	N <u>o</u> of results		
PubMed	All field	2/2/2025	(Vonoprazan OR Voquezna OR "TAK-438" OR "TAK 438" OR TAK438 OR "potassium-competitive acid blocker" OR P-CAB) AND ("transplant*" OR "graft*")	12		
Cochrane	Title/Abstract/keywor d	2/2/2025				
Scopus	Title/Abstract/keywor d	2/2/2025		26		
wos	All field	2/2/2025		13		
Embase	Title/Abstract	2/2/2025		33		
VHL	Title/Abstract	2/2/2025		1		
CINAHL	Title/Abstract	2/2/2025		8		
Total						




Figure S1. The heterogeneity was best resolved by excluding Hidaka et al. Sensitivity analysis of the Change in AST




Figure S2. The heterogeneity was best resolved by excluding Suzuki et al. Sensitivity Tacrolimus trough (C0).

Study		Mean		MRAW	95%-CI	P-value	Tau2	Tau	12
Omitting Hidaka et al. 2022 Omitting Suzuki et al. 2021 Omitting Mei et al. 2020	← ← ← 2	 	8	1.07	[-6.77; 3.93] [-0.17; 2.31] [-7.52; 4.73]		12.8676 0 15.3267	0	0%

Figure S3. The heterogeneity was best resolved by excluding Suzuki et al.